Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Brad Loncar - Investing in Biotech, Chinese Biopharma & The Immunocology ETF

Brad Loncar - Investing in Biotech, Chinese Biopharma & The Immunocology ETF

FromOpto Sessions – Invest in the Next Big Idea


Brad Loncar - Investing in Biotech, Chinese Biopharma & The Immunocology ETF

FromOpto Sessions – Invest in the Next Big Idea

ratings:
Length:
76 minutes
Released:
Jul 1, 2021
Format:
Podcast episode

Description

Brad Loncar is a Biotechnology expert, a pioneer in Biotech investment, and the index provider for two Nasdaq-listed biotech ETFs, Loncar’s Cancer Immunotherapy ETF, and the China BioPharma ETF.  Brad is CEO of Loncar Investments and has a wealth of investment experience, having started out at Franklin Templeton as part of their Management Training Program. Brad’s also spent time in the US political sphere, having been appointed Senior Advisor at the U.S. Department of the Treasury, in between an Investment Directorship in the Bush-Cheney administration in 2004, and a short tenure as Director of Administration for John McCain, in 2008.  Brad currently shares his expertise on LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. We discuss the rampant innovation transforming a constantly evolving industry, before examining Loncar’s two unique ETFs. We finish the interview by looking ahead, where Brad highlights his favourite innovations at the cutting-edge of Biotechnology. Enjoy!Thanks to Cofruition for consulting on and producing the podcast. Want further Opto insights? Check out our daily newsletter: https://www.cmcmarkets.com/en-gb/opto/newsletter
Released:
Jul 1, 2021
Format:
Podcast episode

Titles in the series (100)

Stock Market Opportunities: Opto Sessions brings you in-depth interviews with the best minds in finance, from hedge fund managers to options traders, uncovering their secrets to success. Join us to keep on top of where the industry is going next and learn from the industry's sharpest minds.